Actriib-fc polynucleotides, polypeptides, and compositions
AssigneeAcceleron Pharma Inc.
InventorsJohn Knopf, Jasbir Seehra
Life of this patent
Estimating the term…
Abstract
In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuron. The present invention also provides methods of screening compounds that modulate activity of an ActRII protein and/or an ActRII ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRII protein and/or an ActRII ligand.
Claims16
1-14. (canceled)
A soluble ActRIIB polypeptide comprising an extracellular domain of an ActRIIB polypeptide comprising an amino acid sequence that is at least 80% identical to SEQ ID NO:
- 2, a linker having the sequence TGGG, and an immunoglobulin Fc domain, wherein the immunoglobulin Fc domain is fused to the extracellular domain of the ActRIIB polypeptide by the linker, and wherein the extracellular domain of the ActRIIB polypeptide comprises one or more mutations at a residue selected from:
- L79, D80, and F82, using the amino acid numbering of SEQ ID NO:4.
Dependencies are inferred from the claim text.